altretamine

Medically Reviewed on 8/11/2023

Generic Name: altretamine

Brand Name: Hexalen

Drug Class: Antineoplastics, Alkylating

What is altretamine, and what is it used for?

Altretamine is an oral drug that is used to treat ovarian cancer. The precise mechanism by which altretamine exerts its anti-cancer effect is unknown. It was approved by the FDA in 1990.

What are the side effects of altretamine?

Common side effects are:

What is the dosage for altretamine?

The dose of altretamine is 260 mg/square meter/day. Altretamine may be taken either for 14 or 21 consecutive days as part of one or more 28 day cycles. The total daily dose generally is split into four oral doses, one oral dose after each meal and at bedtime.

Pregnancy and breastfeeding

It is not known whether altretamine is secreted in human milk. Since altretamine may be toxic to nursing infants, breastfeeding is not recommended during treatment with altretamine.

What else should I know about altretamine?

What preparations of altretamine are available?

Capsules of 50 mg.

How should I keep altretamine stored?

Capsules should be stored at room temperature, 15 C to 30 C (59 F to 86 F).

White blood cell counts and platelet counts may drop with altretamine treatment, increasing the risk of infection and bleeding, respectively.

SLIDESHOW

Signs of Cancer in Women: Symptoms You Can't Ignore See Slideshow

Summary

Altretamine is an oral medication prescribed for the treatment of ovarian cancer. Common side effects are nausea and vomiting, peripheral neuropathy, and central nervous system symptoms (mood disorders, disorders of consciousness, ataxia), dizziness, and vertigo. Consult your doctor if pregnant. Do not take if breastfeeding.

Treatment & Diagnosis

Medications & Supplements

FDA Logo

Report Problems to the Food and Drug Administration

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.

See more info: altretamine on RxList
Medically Reviewed on 8/11/2023
References
FDA Prescribing Information